Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 2/20 | 0.60 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.51 |
| ▸ | MAOB | P27338 | 4/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CDK4 | P11802 | 1/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.43 |
| ▸ | CCND1 | P24385 | 1/20 | 0.43 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.43 |
| ▸ | SLC26A4 | O43511 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4198833 | 0.84 | AR (0.54) | ARMRGPRX4MAOBPGRSLC22A12 | |
| SCHEMBL14618854 | 0.83 | MRGPRX4 (0.54) | ARMRGPRX4MAOBSLC22A12 | |
| SCHEMBL4200879 | 0.83 | AR (0.53) | ARMRGPRX4MAOBSLC22A12 | |
| SCHEMBL27459957 | 0.80 | ALOX5 (0.54) | MAOBACHEKDM4ECCNB2CDK1 | |
| SCHEMBL4075116 | 0.80 | MAOB (0.74) | ARMRGPRX4MAOBALOX5 | |
| SCHEMBL6214015 | 0.78 | PTGDR2 (0.47) | ARMRGPRX4CDK4CCND1 | |
| SCHEMBL23235776 | 0.77 | MAOB (0.59) | MAOBACHEKDM4ECCNB2CDK1 | |
| SCHEMBL4202298 | 0.77 | MRGPRX4 (0.66) | ARMRGPRX4MAOBACHE | |
| SCHEMBL4175953 | 0.75 | AR (1.00) | ARPGRSLC22A12 | |
| SCHEMBL13577008 | 0.75 | ACHE (0.49) | MAOBACHEKDM4ECCNB2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170886-A1 | ANDROGEN MODULATORS | PFIZER INC | 2009-07-02 | — | — | US | disclosed |
| US-20090170886-A1 | ANDROGEN MODULATORS | PFIZER INC | 2009-07-02 | — | — | US | disclosed |
| US-20090170886-A1 | ANDROGEN MODULATORS | PFIZER INC | 2009-07-02 | — | — | US | disclosed |
| WO-2007017754-A2 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170886-A1 | ANDROGEN MODULATORS | AR, NR5A1, SHBG | AR 1/4885MRGPRX4 1139/4885MAOB 1336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.